Buy & Sell Abeona Therapeutics Inc (ABEO) – Abeona Therapeutics Inc Price Today
Aura AI Summary
Key Stats
- $327.72MMarket Cap
- HealthSector
- -14.81%3M Drawdown
- $182.62MEnterprise Value
- -Dividend Yield
- 0% Buy | 100% SellTrading Activity
- 18 daysTypical Hold Time
Abeona Therapeutics Inc (ABEO) is currently valued at a market capitalization of $327.72M, with an enterprise value of $182.62M. Over the past 52 weeks, Abeona Therapeutics Inc has traded between a low of $4.17 and a high of $7.23, highlighting its annual price range. Over the past three months, Abeona Therapeutics Inc has recorded a drawdown of -14.81%, reflecting recent price volatility. On average, investors hold Abeona Therapeutics Inc for approximately 18 days, indicating typical investor behavior on the platform.
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Most Recent News
ASE Technology sees AI chip demand boost but insider selling and high valuation raise caution.
ASE Technology Holding Co Ltd reported strong growth driven by demand for AI chip packaging, with gross margins rising to 20.1% from 16.8% year-over-year. The company expects its advanced packaging revenue to exceed $3.5 billion in 2026, reflecting r...

Over 20 pharma firms actively develop 25+ drugs for acute kidney injury treatment, signaling strong pipeline growth.
More than 20 pharmaceutical companies are actively researching and developing over 25 drugs for acute kidney injury (AKI), a condition causing sudden kidney function decline. Key players like AstraZeneca and Akebia Therapeutics are advancing therapie...

Law firm probes fairness of shareholder deals in Dana, Roku, TruBridge, Affinity Bancshares sales
Halper Sadeh LLC is investigating whether shareholders of Dana Incorporated, Roku, TruBridge, and Affinity Bancshares are receiving fair treatment in their companies' proposed sales. The firm highlights potential conflicts where insiders might gain b...
